ARS Pharmaceuticals Inc (NAS:SPRY)
$ 8.88 -0.1 (-1.11%) Market Cap: 860.43 Mil Enterprise Value: 646.70 Mil PE Ratio: 0 PB Ratio: 3.87 GF Score: 19/100

Silverback Therapeutics Inc SBT6050 Clinical Data Update Call Transcript

Sep 16, 2021 / 10:30AM GMT
Operator

Good morning, and welcome to Silverback Therapeutics Investor Event discussing interim data from the SBT-6050-101 clinical study presented at the European Society of Medical Oncology. After the company's prepared remarks, participants will have the opportunity to ask questions. (Operator Instructions)

Please be advised that today's conference may be recorded. (Operator Instructions)

I will now turn over the presentation to Dr. Laura Shawver, CEO of Silverback.

Laura Shawver

Thank you, operator. Good morning, and thanks to everyone for joining us today. We are pleased to discuss the data presented in our ESMO poster from our ongoing Phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors. These data are highlighted by enrollment of 40 patients, giving us confidence in the selection of a projected recommended Phase II dose based on safety and tolerability, PK assessments, PD assessments as well as signals of antitumor activity in the heavily pretreated population. .

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot